- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.01. | Moderna jumps into pivotal pack with promising RSV data as big rivals face off in megablockbuster race | ||
| 17.01. | ICER: Majority of payer coverage policies support 'key elements of fair access' in formularies | ||
| 17.01. | Pfizer inks deal to snatch Abzena's new North Carolina manufacturing site | ||
| 17.01. | CMS initiates coverage analysis for provider-administered PrEP to prevent HIV | ||
| 17.01. | FDA offers new draft guidance on cancer drug dose optimization with overhaul of maximum tolerated dose paradigm | ||
| 17.01. | PwC predicts 'flurry' of $5B to $15B biotech deals in 2023 | ||
| 17.01. | Biden's chief science officer for Covid-19 steps down amid dearth of top leadership | ||
| 17.01. | Drug name review: Science takes the spotlight in 2022 | ||
| 17.01. | Aeterna discontinues vaccine development; Idera Pharmaceuticals rebrands as Aceragen | ||
| 17.01. | Pfizer shifts full portfolio to non-profit model in 45 lower-income countries | ||
| 17.01. | Following Alzheimer's drug approval, analysts dish on what they expect from Biogen in 2023 | ||
| 17.01. | MarketingRx roundup: Eli Lilly debuts unbranded 'memory' issues TV ad; Big Pharmas amp social media spending | ||
| 17.01. | Leap Therapeutics jumps into growing Claudin18.2 field by buying Flame Biosciences | ||
| 17.01. | NewAmsterdam notches another win in resurrection of Amgen cardio drug | ||
| 17.01. | AbbVie, Eli Lilly quit UK's voluntary drug pricing agreement, sending 'warning signal' to UK government | ||
| 17.01. | Cancer vaccine developer jumps to Nasdaq via reverse merger | ||
| 16.01. | Latest news on Covid boosters safety signal; AstraZeneca leads trio of M&A; The biggest news out of JPM23; and more | ||
| 14.01. | US investigates potential safety signal with Pfizer Covid boosters | ||
| 13.01. | California sues insulin heavyweights, PBMs over 'excessive' prices | ||
| 13.01. | Ex-Takeda staffer's 'small hustle' ends with arrest and $2.3M fraud charge | ||
| 13.01. | EMA developing physician guidance for potential liver damage after taking Zolgensma | ||
| 13.01. | Myovant, Pfizer debut first branded campaign for prostate cancer med Orgovyx | ||
| 13.01. | Most trusted: Pharma overtakes tech industry for top spot in Ipsos' annual trustworthiness survey | ||
| 13.01. | Scoop: Roche-backed startup gives up on CD47 as CEO, most employees leave | ||
| 13.01. | In 'clever' experiment, scientists use gene editing to treat heart disease in mice |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
